Skip to Main Content

Paper Details

PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
J Am Heart Assoc
39
2019
LDL, LDL (low-density lipoprotein, LDL cholesterol, PCSK9, Participants, Patient, Patients, atherosclerotic cardiovascular disease, cholesterol, coronary artery disease, coronary heart disease, dyslipidemia, patient, patients, proprotein convertase subtilisin/kexin type 9
Author NameAffiliation
Alanna M Chamberlain1 Mayo Clinic Rochester MN.
Jiang Bian3 College of Medicine University of Florida Gainesville FL.
Rashmee U Shah10 University of Utah Salt Lake City UT.
Elizabeth A Shenkman3 College of Medicine University of Florida Gainesville FL.
Elizabeth A Shenkman3 College of Medicine University of Florida Gainesville FL.
Pamala A Pawloski12 HealthPartners Institute Minneapolis MN.
Adrian F Hernandez13 Duke University Durham NC.
Rhonda M Cooper-DeHoff4 Colleges of Pharmacy and Medicine University of Florida Gainesville FL.
  • 1 - 8

Datasets

Release 1.2